Search
for
Sort by
Research 31–60 of 38
- Tissue engineering of skin and regenerative medicine for wound care
- Advances and Innovations of 3D Bioprinting Skin
- Fibroblasts in Diabetic Foot Ulcers
- Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments
- The 3D Bioprinted Scaffolds for Wound Healing
- Overview of Urethral Reconstruction by Tissue Engineering: Current Strategies, Clinical Status and Future Direction
- Advanced 3D/4D Bioprinting of Flexible Conductive Materials for Regenerative Medicine: From Bioinspired Design to Intelligent Regeneration
- Fabrication of Bioactive <i>Helix aspersa</i> Extract-Loaded Chitosan-Based Bilayer Wound Dressings for Skin Tissue Regeneration
- Ratanjot (Alkanna Tinctoria L.) Boraginaceae Root Extract, A Miracle Hair Oil
- Ratanjot (Alkanna Tinctoria L.) Boraginaceae Root Extract, A Miracle Hair Oil
- Formulation and Evaluation of Liposomal Herbal Hair Serum Using Alkanet Root Extract
- Hair Colours/Dyes
- How to defeat male pattern alopecia in a trompeur de femmes, who loves to abuse of libido boosters?
- COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine
- GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk
- Body image mediates the impact of pain on depressive symptoms in patients with systemic lupus erythematosus
- Illustrated Manual of Pediatric Dermatology
- A novel <i>MBTPS2</i> variant associated with BRESHECK syndrome impairs sterol‐regulated transcription and the endoplasmic reticulum stress response
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- 75893 Long-term efficacy, complete scalp hair regrowth and normal body hair/nails in adolescents with severe alopecia areata (AA) receiving ritlecitinib up to 3 years in the ALLEGRO clinical trials
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Understanding the Impact of Reperfusion in the Development of a Safe Compression Therapy
- GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk
- Author response: Smad4 restricts differentiation to promote expansion of satellite cell derived progenitors during skeletal muscle regeneration
- Bioprinting of skin constructs for wound healing
- Steroid 5α-reductase 2 deficiency leads to reduced dominance-related and impulse-control behaviors
- Pannexin 3 regulates skin development via Epiprofin
- Intraoperative Bioprinting of Human Adipose-derived Stem cells and Extra-cellular Matrix Induces Hair Follicle-Like Downgrowths and Adipose Tissue Formation during Full-thickness Craniomaxillofacial Skin Reconstruction